The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research
 
Brian Michael Alexander
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Roche
Research Funding - Celgene (Inst); Lilly (Inst); Puma Biotechnology (Inst)
 
Donald A. Berry
Employment - Berry Consultants
Leadership - Berry Consultants
Stock and Other Ownership Interests - Berry Consultants
Consulting or Advisory Role - Berry Consultants
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Berry Consultants
 
Howard Colman
Consulting or Advisory Role - Abbvie; Adastra Pharmaceuticals; Adastra Pharmaceuticals; Bayer; Best Doctors, Inc; FORMA Therapeutics; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bayer; BeiGene (Inst); Bristol-Myers Squibb; DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Nuvation Bio; Orbus Therapeutics (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; FORMA Therapeutics; Karyopharm Therapeutics; Orbus Therapeutics
 
John Frederick de Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; WuXi Biologics; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; Bioasis Technologies; Cure Brain Cancer Foundation; Debiopharm Group; DelMar Pharmaceuticals; Genentech/Roche; GenomiCare; GlaxoSmithKline; InSightec; Janssen; Karyopharm Therapeutics; KIYATEC; Magnolia Innovation; Merck; Monteris Medical; Mundipharma Research; Novartis; Prelude Therapeutics; resTORbio; Samus Therapeutics; Sapience Therapeutics; Tocagen; Voyager Therapeutics
Research Funding - CarThera (Inst); Haihe Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - VBI Vaccines
 
Benjamin M. Ellingson
Consulting or Advisory Role - Alpheus Medical; Chimerix; Ellipses Pharma; Global Coalition for Adaptive Research; Imaging Endpoints; ImmunoGenesis; Janssen; Kazia Therapeutics; Medicenna; MedQIA; Monteris Medical; Neosoma; SERVIER; Siemens; Sumitomo Dainippon Pharma Oncology; VBL Therapeutics
Research Funding - Janssen; Siemens
Travel, Accommodations, Expenses - Siemens
 
Gary B. Gordon
Employment - Ayala Pharmaceuticals
Leadership - Ayala Pharmaceuticals; Biosight; PhotonPharma
Stock and Other Ownership Interests - Abbott; Abbvie; Ayala Pharmaceuticals; Imago Pharma; Medtronic; Merck
Consulting or Advisory Role - Biosight; Imago Pharma; Molecular Templates
Other Relationship - Global Coalition for Adaptive Research
 
Mustafa Khasraw
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Janssen; Lilly; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Andrew B. Lassman
Consulting or Advisory Role - Bayer; BioClinica; Chimerix; Elsevier; Karyopharm Therapeutics; Novocure; Orbus Therapeutics; Sapience Therapeutics; Vivacitas Oncology
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Bayer (Inst); BeiGene (Inst); BMS (Inst); Chimerix (Inst); Corden (Inst); DelMar Pharmaceuticals (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Millennium (Inst); NextSource (Inst); Novartis (Inst); Novocure (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); Semus (Inst); Servier (Inst); VBI Vaccines (Inst)
Travel, Accommodations, Expenses - Chimerix; Karyopharm Therapeutics; Novartis; Novocure; Orbus Therapeutics; Pfizer; QED Therapeutics; VBI Vaccines
 
Eudocia Quant Lee
Honoraria - Continuum (American Academy of Neurology); Medlink
Consulting or Advisory Role - Medscape
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Michael Lim
Stock and Other Ownership Interests - Egret Bioscience
Honoraria - Accuray; Agenus; Bristol-Myers Squibb; Merck; Oncorus; Stryker; tocagen
Consulting or Advisory Role - Accuray; Baxter; Bristol-Myers Squibb; InCephalo Therapeutics/University of Zurich; Insightec; Merck; PepVax; Pyramid Biosciences; Stryker; VBI Vaccines
Research Funding - Accuray (Inst); Agenus (Inst); Arbor Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); CellDex (Inst); ImmunoCellular Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Methods Patent for Combining Immunotherapy with Radiation (Inst)
Travel, Accommodations, Expenses - Accuray; Baxter; Bristol-Myers Squibb; Merck; Stryker
 
Ingo K. Mellinghoff
Honoraria - Black Diamond Therapeutics; Hartford HealthCare; Prelude Therapeutics; Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Cardinal Health; Debiopharm Group; Divide and Conquer; Global Coalition for Adaptive Research; Novartis; Roche; SERVIER; Voyager Therapeutics
Research Funding - Amgen; General Electric; Kazia Therapeutics; Lilly; SERVIER
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics
 
Apoorva Nelli
Research Funding - Amgen (Inst); Bayer (Inst); Eisai (Inst); Kazia Therapeutics (Inst); Kintara Therapeutics (Inst)
 
James R. Perry
No Relationships to Disclose
 
Erik P. Sulman
Honoraria - Novocure; Zai Lab
Research Funding - Novocure (Inst)
 
Kirk Tanner
Stock and Other Ownership Interests - Blueprint Medicines; Bright Horizons; Disney; Labradory Holdings; Lilly; Moderna Therapeutics; Pfizer; Relay Therapeutics; Roblox; Vertex
Honoraria - Inovio Pharmaceuticals; Sage Therapeutics
Consulting or Advisory Role - Oncoheroes Biosciences; Sage Therapeutics; Telo Therapeutics
Other Relationship - Cordance Medical; Telo Therapeutics
 
Michael Weller
Honoraria - Adastra Pharmaceuticals; Merck Serono; Nerviano Medical Sciences; Philogen
Consulting or Advisory Role - Bristol-Myers Squibb; Karyopharm Therapeutics; Medac; Orbus Therapeutics; Ymabs Therapeutics Inc
Research Funding - Apogenix (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); Quercegen Pharmaceuticals (Inst)
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Black Diamond Therapeutics; Blue Earth Diagnostics; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Imvax; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Nuvation Bio; Prelude Therapeutics; QED Therapeutics; Sapience Therapeutics; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Research Funding - Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
W. K. Alfred Yung
Stock and Other Ownership Interests - De Novo Pharmaceuticals; DNATrix; Quadriga
Honoraria - Roche
Consulting or Advisory Role - Denovo Biopharma; DNAtrix; ILCT; Quadriga; Roche
Patents, Royalties, Other Intellectual Property - DNATrix